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Abstract
Background: Von Hippel-Lindau (VHL) disease is a rare oncological disease with an incidence of 1:36,000, and is
characterized by the growth of different types of tumours. Haemangioblastomas in the central nervous system
(CNS) and retina, renal carcinoma and pheochromocytomas are the most common tumours. The absence of
treatment for VHL leads to the need of repeated surgeries as the only option for these patients. Targeting VHL-
derived tumours with drugs with reduced side effects is urgent to avoid repeated CNS surgeries. Recent reports
have demonstrated that propranolol, a β-blocker used for the treatment of hypertension and other cardiac and
neurological diseases, is the best option for infantile hemangioma (IH). Propranolol could be an efficient treatment
to control haemangioblastoma growth in VHL disease given its antiangiogenic effects that were recently
demonstrated by us. The main objective of the present study was the assessment of the efficacy and safety of
propranolol on retinal haemangioblastoma in von Hippel-Lindau disease (VHL).
Methods: 7 VHL patients, from different regions of Spain, affected from juxtapapillary or peripheral
haemangioblastomas were administered 120 mg propranolol daily. Patients were evaluated every 3 months for
12 months, at Virgen de la Salud Hospital (Toledo). The patients had juxtapapillary or peripheral haemangioblastomas
but had refused standard treatments.
Results: Propranolol was initiated with a progressive increase up to a final dose of 120 mg daily. All tumours remained
stable, and no new tumours appeared. The reabsorption of retinal exudation was noted in the two patients having
exudates. No adverse effects were recorded. VEGF and miRNA 210 levels were monitored in the plasma of patients as
possible biomarkers of VHL. These levels decreased in all cases from the first month of treatment.
Conclusions: Although more studies are necessary, the results of this work suggest that propranolol is a drug to be
considered in the treatment of VHL patients with retinal haemangioblastomas. VEGF and miRNA 210 could be used as
biomarkers of the VHL disease activity.
Trial registration: The study has a clinical trial design and was registered at EU Clinical Trials Register and Spanish
Clinical Studies Registry, EudraCT Number: 2014–003671-30. Registered 2 September 2014.
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Background
Von Hippel-Lindau disease is a rare, genetic, hereditary,
highly disabling and debilitating disease, which frequently
leads to premature death. Von Hippel-Lindau disease is a
familiar cancerous disease, with a dominant pattern of in-
heritance. Its incidence in the population is 1/36,000 [1].
Clinical manifestations include multiple benign and
malignant tumours that appear throughout the lifespan
of the patient: haemangioblastomas in the central ner-
vous system and retina and cysts and tumours at other
levels (serous cystadenoma and pancreatic neuroendo-
crine tumours, renal clear cell carcinoma and renal
cysts, endolymphatic sac tumor, pheochromocytoma and
paraganglioma, and cystadenoma of the epididymis and
broad ligament) [1, 2].
Retinal haemangioblastomas are typically the most com-
mon and earliest presentation of VHL disease [1, 3],.
These lesions can occur in about 50% of the VHL patients
and mark the debut of the disease in one third of cases.
The mean age at diagnosis is 25 years (range: 1–68 years),
but these lesions can occur also in infancy [2, 4]. These tu-
mours are often multiple and bilateral, and their size var-
ies from less than one to several optic discs in diameter.
Pathologically identical to the CNS haemangioblasto-
mas [5, 6], these lesions can be classified as peripheral
and juxtapapillary (when appear on the optic nerve or
near it). Both peripheral and central hemangiomas may
cause exudative and tractional retinal detachment, hae-
morrhages, glaucoma and cataract, leading to blindness.
Unilateral or bilateral amaurosis is relatively frequent
among the VHL population due to the development of
multiple tumours, which in many cases could be pre-
vented or delayed with proper monitoring and early treat-
ment. When these lesions begin to grow, they are
extremely small and difficult to visualize. Generally small
lesions can be treated with greater success and fewer com-
plications compared with larger ones [7]. Most peripheral
retinal tumours can be treated with laser photocoagula-
tion (small peripheral tumours) or cryotherapy (larger tu-
mours), but these current treatments cannot be used
when the tumor is near the optic nerve. In these cases, the
most generalized therapeutic approach is only surveil-
lance, given the high risk of damaging the optic nerve [2].
Photodynamic therapy has been used with uneven re-
sults [8–12]. Some antiangiogenic drugs, such as bevaci-
zumab and ranibizumab, have been used [13–15], but
they do not provide long-term cessation of tumours’
growth [16, 17]. To date no treatment has proven effect-
ive in changing the course of the disease, and the possi-
bility that these patients experience improvement when
treated with propranolol is undoubtedly an outstanding
therapeutic need.
Propranolol hydrochloride is a synthetic β-adrenergic
receptor blocking agent marketed for more than 50 years,
and whose safety has been largely demonstrated. It has
recently been approved for a new indication: the treat-
ment of proliferative infantile haemangioma. This drug
has several potential mechanisms of action described in
the literature: local haemodynamic effect, antiangiogenic,
apoptosis of capillary endothelial cells and reduction of
signalling pathways VEGF and bFGF [18, 19].
Previous evidences in the literature demonstrated that
propranolol, a drug used to treat arrhythmias, migraines,
hypertension and other cardiac and neurological diseases,
is effective in the treatment of infantile hemangioma, the
most common vascular tumour in new-borns. Its effect
was discovered by chance in 2008 [20] and propranolol is
the treatment of choice for this vascular tumour.
Propranolol has recently begun to be tested in breast
cancer (ClinicalTrials.gov Identifier: NCT01847001) and
melanoma (ClinicalTrials.gov Identifier: NCT02962947),
after clinical evidence suggesting that the use of beta-
blockers such as propranolol, could increase relapse-free
and overall survival [21–24]. The data from previous
studies with propranolol to treat angiomas at different
levels -, including airway [25, 26] and cerebral cavernous
angioma [27–29], support the plausibility of experimen-
tal use in this rare disease with a poor prognosis and no
pharmacological treatment.
Specifically focusing on retinal pathology, several case re-
ports using propranolol for the treatment of diffuse chor-
oidal haemangiomas typical of Sturge-Weber syndrome
have recently been published, with positive results [30].
Given that haemangioblastomas are proliferative vas-
cular tumours, and the natural evolution of papillary
and juxtapapillary tumours in VHL disease leads to am-
aurosis, we hypothesized that propranolol could also
function to reduce the growth of those retinal haeman-
gioblastomas where the use of standard treatments could
trigger a rapid loss of vision. We propose an experimen-
tal use of propranolol as a therapeutic alternative. Based
on previous results of propranolol efficiency for IH treat-
ment [18, 31–33] and our own results demonstrating
that propranolol acts as antiangiogenic in endothelial
cells [34], we hypothesized that propranolol could act by
decreasing HIF levels and thereby downregulating the
HIF target program. Interestingly, all the HIF target
genes, including VEGF (Vascular endothelial growth fac-
tor), MMPs (Metalloproteases), EPO (Eritropoietin) or
FGF (Fibroblast growth factor), among others, are abso-
lutely necessary for the survival and progression of tu-
mours in general and for haemangioblastomas in
particular. Haemangioblastomas are complex tumours
consisting of different cellular types, with stromal (undif-
ferentiated mesenchymal cells) and endothelial cells as
the main components. When haemangioblastoma cells
are subjected to long-term propranolol treatment, hae-
mangioblastoma cells first stop proliferating, and then
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cell death is detected from the empty spaces in the
plates. As explained by previous results, the death must
be attributed to apoptosis [35]. Therefore, these results
led us to consider the hypothesis that propranolol could
be an efficient treatment for haemangioblastomas,
through inhibition of HIF and consequently all of its
gene targets in highly vascularized tumours, where HIF
is constitutively expressed. One of the crucial HIF tar-
geting actions is the angiogenesis process via VEGF. We
suggest that propranolol acts therefore by an antiangio-
genic mechanism, with VEGF being one of the downreg-
ulated genes by the propranolol treatment.
With this background in mind, we hypothesized the
following:
 Null hypothesis for the primary endpoint: retinal
haemangioblastomas progress in size or complications
from baseline value to the end of the treatment period
at the 12th month.
 Alternative hypothesis: retinal haemangioblastomas
have decreased in size or remain stable compared to
baseline, after the completion of the treatment period.
Methods
We designed an open, pilot clinical trial, to evaluate the
effectiveness and safety of propranolol administered over
a period of 1 year, for te treatment of patients with von
Hippel-Lindau disease and papillary or juxtapapillary hae-
mangioblastoma non eligible for standard treatment (laser
or cryotherapy), or peripheral retinal haemangioblastomas
for which patients had rejected standard therapies. A total
of 7 VHL patients who met the inclusion criteria were re-
cruited. The study included clinic visits at Virgen de la
Salud Hospital (Toledo), at baseline and at months 1, 3, 6,
9 and 12 of treatment. A follow-up visit was scheduled
after approximately 30 days for patients who were with-
drawn from the study. EudraCT Number: 2014–003671-
30. Registered 22 September 2014.
The primary endpoint of the study was the measure-
ment of the number and size of haemangioblastomas.
The secondary end points were the visual acuity, exud-
ation and exudative retinal detachment. As exploratory
objetives, the detection and quantification of plasma bio-
marckers, VEGF and miRNA 210 and the detection of
HIF-controlled targets in the PBLs (peripheral blood leu-
kocytes) of the patients along the trial were performed.
The biomarkers study could serve to check a possible re-
lationship between them and the evolution of the disease.
The patients didn’t receive any other treatment which
could interfere with the outcomes of the clinical trial.
The Spanish association of patients Alianza VHL in-
formed their members of the study during its annual
meeting and through the internet, inviting VHL
patients with juxtapapillary tumours to participate in
the clinical trial.
Inclusion criteria: patients diagnosed with von
Hippel-Lindau disease presenting ocular involvement
due to typical haemangioblastomas appearing in the ret-
ina in the course of the disease. Within this population,
patients were selected if they met one of two criteria:
1. Papillary or juxtapapillary haemangioblastoma, non-
eligible for standard treatment (laser photocoagulation
or cryotherapy) due to the high risk of visual loss.
2. Peripheral retinal haemangioblastomas for which
patients had rejected standard treatments.
The pharmaceutical form and strength used was pro-
pranolol 40 mg, film-coated tablets, 1 every 8 h up to a
total dosage of 120 mg/day. At this dose, the safety and
tolerability of the drug is acceptable. Nevertheless, an
experienced cardiologist in handling propranolol, moni-
tored closely the treatment and the response of patients.
In each visit, blood was extracted for the quantification
of molecular biomarkers in the research sub-study.
VEGF determination in plasma
A Quantikine Human VEGF ELISA kit from R&D Sys-
tems (Abingdon, UK) was used to quantitatively deter-
mine human VEGF-A concentrations in plasma of the
patients included in the study during the different visits
from 0 to 12 months of propranolol treatment.
Real-time RT (RT-qPCR)
Total cellular RNA was extracted from peripheral blood
cells (PBLs) from each patient following the clinical trial,
using a Nucleo Spin RNA kit (Macherey-Nagel, Düren,
Germany). One microgram of total RNA was reverse-
transcribed in a final volume of 20 μl with the First Strand
cDNA Synthesis Kit (Roche, Mannheim, Germany) using
random primers. The SYBR Green PCR system (BioRad,
Hercules, CA, USA) was used to perform real-time PCR
with an iQ5 system (Biorad, Spain). The sequences of the
oligonucleotides used corresponded to the following
shown in Table 1:
As an internal control, mRNA levels of 18S were mea-
sured. Amplicons were detected using an iQ5 system
(BioRad). The samples were assessed in triplicate and
the experiment was repeated twice.
miRNA 210 plasma quantification
Total RNA was isolated from 50 μl of plasma using miR-
neasy kit (Qiagen) and resuspended in 40 μl. Relative
miRNA levels were normalized to one spike-in miRNAs:
cel-miR-39, 5′-UCACCGGGUG UAAAUCAGCUUG-3′
(Applied Biosciences).
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Kits: sequences for qPCR of human miR 210 and cel-
miR39 were ordered from Quantabiosciences. In addition
the following kits were used for the reverse transcription
and the PCR synthesis: qScript™ microRNA cDNA
Synthesis Kit and PerfeCTa ® Universal PCR from Quanta.
The procedure followed all the manufacturer instructions.
Statistics
Given that this is a pilot clinical trial, statistics data were
not planned beforehand. Moreover, it is unlikely that we
will obtain statistical power for tumour size with only
seven patients. However, molecular data on biomarkers
were subjected to statistical analysis. The data represent
mean ± SD. Differences in mean values were analysed
using the Student’s t-test. P-values of <0.05 were consid-
ered to be statistically significant; statistically significant
values are indicated with asterisks (*P < 0.05; **P < 0.01;
***P < 0.005).
Results
Seven patients volunteered for the study. Some of them
decided to participate because their tumours continued
progress despite treatment with laser photocoagulation.
Four patients had previous severe effects, including im-
paired vision, as a result of exudation due to active tu-
mours. Two patients had a recent diagnosis of VHL
disease. One patient was lost to follow-up because she
had to undergo a programmed surgery and did not con-
tinue afterwards.
Table 2 shows the age, sex, type of mutation and sum-
mary of the main clinical outcomes.
All patients visited the Ophthalmology Department at
Virgen de la Salud Hospital after 1 month, and then,
every 3 months. The Ophthalmologist researcher took
pictures of the affected retina in each visit.
As the main clinical outcomes (Table 1), the number
and size of all the tumours present on the retina, in all
patients, remained stable during the clinical trial, with-
out any other treatment, regardless of propranolol
administration. Tumor size was measured at the begin-
ning and at each visit (data not shown). No significant
changes in size were noted. However, no new tumours
appeared during the follow-up period. The most remark-
able result was the reabsorption of exudates in the 2 pa-
tients with retinal exudation. The disappearance of the
lesion was progressive and clear. The patients did not re-
ceive any other treatment that could interfere with the
outcomes of our clinical trial.
Of note, without treatment, and occasionally with
treatment, retinal haemangioblastomas can continue to
grow and affect visual function by causing an exudative
retinal detachment [7]. The only method to reduce the
exudation is laser coagulation or cryotherapy of tumour
feeding vessels, if possible.
Table 1 Primers used for qPCR amplications
GENE Forward Reverse
18S 5′- CTCAACACGGGAAACCTCAC - 3′ 5′-CGCTCCACCAACTAAGAACG - 3′.
BAX 5′- CACTCCCGCCACAAAGAT - 3′ 5′- CAAGACCAGGGTGGTTGG - 3′
EPO 5′ - TGTTTTCGCACCTACCATCA - 3′ 5′ - AAGTCACAGCTTGCCACCT - 3′
SOX2 5′ – GGGGGAATGGACCTTGTATAG - 3′ 5′ – CGCTCCACCAACTAAGAACG - 3′
OCT4 5′- CTTCGGATTTCGTCTTCTCG-3′ 5′- CTTAGCCAGGTCCGAGGAT - 3′
Table 2 Genetics and active tumours of the patients along the clinical trial
First visit Last visit (12 months later)
Patient Age Gender Gene VHL locus Mutation Left eye Right eye
Tumours Exudation Tumours Exudation Tumoursa Exudation
1 36 M Intron 2 Splice g. 8665, A > G;
c.DNA 463,+2A > C
1 peripheral - 1 peripheral Great exudation No changes No exudation
2 33 F Intron 2 Splice.g.8665, A >
G; c.DNA 463,+2A > C
1 juxtapapillary - - - No changes -
3 50 F Exon 3 c.501 A > T 1 juxtapapillary Exudation - - No changes Much less exudation
4 20 M Exon 3 c.501 A > T 1 juxtapapillary - - - No changes -
5 15 M Ex1–2-3 del complete VHL - - 1 peripheral - No changes -
6 38 F Exon 1 del exon 1 1 juxtapapillary - - - Withdrawnb -
7 22 M Exon 3 c.486, C > G 2 peripheral - 2 peripheral No changes -
This table exclusively presents active tumours in the initial or final evaluation, which were the principal objective of treatment
a“No changes” indicates no more tumours, or growth of previous tumours
bWithdrawn from the clinical trial due to a scheduled surgery
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The only side effect observed was low blood pressure
in patient 4. In this case, the dosage of 120 mg/day was
achieved more slowly, with a progressive increase
over more weeks compared with other patients, under
cardiologist control. Hypotension is a well-known and
frequent side effect of beta-blockers, as propranolol,
which can be partially prevented by increasing the
dose slowly.
Data from the clinical registries
In addition to the controls performed by the ophthal-
mologist researcher (Toledo), the patients continued
with their usual controls suggested by their ophthalmol-
ogists at their place of residence. This feature helped us
to be more objective with the interpretation of our re-
sults. The clinical registries of patients before the clinical
trial help to make the outcomes of this trial significant.
The evolution of the registries of some of the patients
are shown in Figs. 1 and 2. Fig. 1a shows the evolution
of patient 1 in a graphic based on the notes written by
ophthalmologists in his clinical history. This patient had
a clinical register with multiple tumours, treated by mul-
tiple photocoagulations. The dotted lines denote the
time under the clinical trial with propranolol treatment.
Ophthalmologist wrote in his clinical history “no new le-
sions/no active lesions” during the visits he attended
from January 2015 until December 2015. Moreover, he
had retinal exudation which decreased during the
months of treatment (Fig. 1b). He had also the most sig-
nificant reduction in VEGF levels during the study, as
shown in Fig. 3.
Fig. 2a presents the evolution of patient 2. She had
several tumours that remained stable in number and
size. Fig. 2b shows evolution of patient 5. The yellow
line indicates the start of treatment with propranolol.
Patient 6 had a severe retinal disease with important
visual impairment. She had to undergo retinal sur-
gery, scheduled before the start of the trial, and was
admitted in case treatment could avoid the surgery,
but finally, as it was necessary, the patient withdrew
from the clinical trial.
Biomarkers used in the clinical trial as indicators of
prognosis
Three types of biomarkers from blood samples have
been used for the patient follow-up: VEGF plasma levels,
given that VEGF is a direct HIF target; qPCR with other
HIF target genes pertinent to the development of hae-
mangioblastomas: Epo, Sox-2 and Oct-4; and the pro-
apoptotic gene Bax.
Finally, as part of an innovative technique, we analysed
the miR210 levels in plasma. Mir210 is a micro-RNA re-
sponsive to hypoxia that we have used as a new putative
biomarker to follow VHL patient evolution during the
clinical trial.
Fig. 1 a Evolution of Patient 1 included in the clinical trial. The graphic is based on the notes written by the different ophthalmologists in his
clinical history, and represents the evolution before and during the clinical trial. The dotted lines denote the time of propranolol administration in
the clinical trial. b The patient had retinal exudation that decreased as treatment progressed, as demonstrated at three different time points
during the clinical trial
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VEGF as a biomarker in circulating plasma
As a marker of angiogenesis related to VHL, and HIF
target, VEGF was measured by ELISA in the plasma
of all the patients, before they started the clinical
trial, and every time they visited the researcher
ophthalmologist. In all patients, VEGF levels decreased
from the first month of treatment. (P = Patient) in a
significant manner (p < 0.001), reaching normal levels
(concentration < 50 pg/ml) in all cases after 3 months of
treatment (Fig. 3).
Fig. 2 Evolution of Patients 2 and 5 included in the clinical trial. a Patient 2: the graphic is based on the notes written by the different ophthalmologists
in his clinical history, and represents the evolution before and during the clinical trial. The dotted lines denote the time of propranolol administration in
the clinical trial. b Patient 5: the graphic is based on the notes written by the different ophthalmologists in his clinical history, and represents the
evolution before and during the clinical trial. The dotted lines denote the time of propranolol administration in the clinical trial
Fig. 3 Evolution of VEGF plasma levels of the different patients (P1-P7) at the different visits during the clinical trial. Arrows indicate three cases
wherein VEGF levels were initially greater than the normal threshold, and the decrease was significant, reaching normal levels following
propranolol treatment
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qPCR of HIF targets and Bax proapoptotic gene during
propranolol treatment
The mRNA expression levels of other HIF-target genes,
Epo, Sox-2 and Oct4 (genes triggered by HIF-1 at
transcription level), and the pro-apoptotic gene Bax
(repressed by the β-adrenergic pathway) were also
assessed by qRT-PCR in the cells of the PBL fraction
from each patient during the clinical trial. Fig. 4
shows reveals a 1.5 to 2.5 fold increase in the Bax
expression and reduced Epo, Sox-2 and Oct4 (genes
involved in angiogenesis, and stemness, respectively)
expression after propranolol treatment. The graphs
are from a representative patient. The results are
compatible with a situation wherein the existing
haemangioblastomas should not proliferate due to
decrease in proangiogenic genes (Epo and VEGF), a
decrease in the expression of tumour progression
genes, Sox-2 and Oct4 and an increase in proapopto-
tic Bax. All cells in patients are heterozygous for the
Vhl gene, with the exception of cells from haeman-
gioblastomas (Vhl −/−). The response to propranolol
treatment is systemic and depending on the β2 adren-
ergic receptors expressed by the cells in the organism.
It is noteworthy to mention that in three cases when
blood cell counts were available before and after the
clinical trial, a decrease of total leukocytes number
was detected, but keeping always values over 4.000
leukocytes/ml within normal range. Moreover, an ab-
normal number of reticulocytes detected in one of
these patients before the clinical trial completely dis-
appeared after propranolol treatment. These data are
in agreement with the increase of Bax during the
clinical trial.
Evolution of mir210
Mir 210 was used as a hypoxia microRNA target in-
duced by HIF [36] and therefore could be a good marker
in parallel with other HIF targets, including Epo, Sox-2
and Oct4; VEGF in plasma and Bax for monitoring the
evolution of the patients in the clinical trial.
As observed in Fig. 5, miR210 was reduced at the be-
ginning of propranolol treatment. Similar results were
noted for VEGF, with the exception of P5 where there
was no significant change. After 3 months of propran-
olol treatment, VEGF was significantly reduced, and
miR210 levels were reduced by half (P2–3 m).
Discussion
The present manuscript shows the results of a pilot clin-
ical trial, with 120 mg/day of propranolol to delay/stop
the growth of retinal haemangioblastomas in VHL pa-
tients. The fact that the number and size of all the tu-
mours present on the retina at the beginning of the
clinical trial remained stable without any other treat-
ment, other than propranolol is quite promising, espe-
cially when compared with the previous evolution of
these patients. One could argue that this result could be
attributable to the natural behaviour of the retinal hae-
mangioblastomas which might be quiescent for this
period. However, the progressive and clear reabsorption
of exudation cannot be explained by tumour quiescence.
The introduction of molecular biomarkers to follow the
patient’s evolution in parallel helped to reinforce the
clinical observations. The concomitant reduction of vas-
cular endothelial growth factor (VEGF) plasma levels, al-
most from the beginning of the treatment is a clear
change that is likely attributable to propranolol.
Fig. 4 RT-PCR results of the relative expression levels of different HIF target genes normalized to 0, following propranolol treatment. The
proapoptotic gene Bax, is upregulated relative to the initial time point during the clinical trial, whereas Epo, Sox, and Oct 4 gene expression is
downregulated in response to propranolol. The results are representative of one of the patients included in the clinical trial. RNA was obtained
from the PBL fraction. Each RT-PCR was repeated at least three times and in triplicate
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As a marker used for the first time in von Hippel-
Lindau disease, we have introduced the micro- RNA
miR210, which is a direct target of HIF [36]. The results
of plasma miR210 detection during the clinical trial, re-
veal an evolution parallel to VEGF. Therefore, in this
context, we could consider plasma levels of VEGF and
miRNA 210 as biomarkers for VHL disease and espe-
cially suggestive of bona fide biomarkers for good prog-
nosis in the evolution of the retinal disease.
If we attempt to correlate VEGF/miR210 levels with
the clinical findings before the start of the treatment, we
realize that the two highest VEGF values in P1 and P3
(280 pg/mL and 120 pg/mL, respectively), correspond to
the two patients harbouring haemangioblastomas with
exudates. These patients exhibited normalized VEGF
levels, after 3 and 1 month, respectively, and miR210
levels were reduced by 60% and 50%. The reabsorption
of exudates began after 3 months, and was almost
complete after 6 months. Therefore, the correspondence
between VEGF/miR210 levels and the clinical outcomes
suggest that these are good VHL biomarkers and further
support their use as good therapeutic monitors during
propranolol treatment.
In vitro results obtained in our lab, suggest that pro-
pranolol decreases HIF levels in haemangioblastoma cell.
Thus, the HIF targets, are at least, partially silenced/de-
creased [35]. Consequently, in the absence of essential
factors for survival (those HIF targets), and due to the
pro-apoptotic effect of propranolol [18, 34, 35] the
tumour cells stop dividing. As a β-blocker, propranolol
reverses three main targets: halting division and trigger-
ing apoptosis, inducing anti-angiogenesis, and promot-
ing vasoconstriction. Thus, on one hand, propranolol
may stop HIF-inducible functions, such as VEGF-, Epo-,
Sox-2- and Oct-4- dependent growth of haemangioblas-
tomas [4, 37], and inhibition of angiogenesis. On the
other hand, propranolol promotes apoptosis by inducing
Bax and the caspase cascade. These two facts together
may contribute to the control of haemangioblastoma
growth. The expression of these genes was also mea-
sured during the clinical trial, supporting the rationale
of propranolol’s way of action and clinical effects. In par-
ticular, the influence of propranolol on apoptosis, likely
explains the role of adrenergic antagonists in the patho-
genesis and therapy of inflammation, cardiovascular dis-
eases, and bronchial asthma [38]. In addition, the total
Fig. 5 RT-PCR results of the miR210 gene as measured from plasma
samples of the patients included in the clinical trial. The quantification
of miR210 before and after 1/3 months (Pre/Post) of propranolol
treatment is presented. All the decreases are significant at p < 0.001
Fig. 6 Hypothesis summarizing the propranolol mechanism involved in haemangioblastoma cells. As a β-blocker, propranolol would reverse three
main targets promoting the cessation of division and apoptosis, anti-angiogenesis, and vasoconstriction
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leukocyte count in those patients with blood tests avail-
able were decreased but keeping the normal range over
4.000 leukocytes/ml. Abnormal number of reticulocytes
disappeared also during propranolol treatment in one
patient. This is in agreement with the influence of pro-
pranolol in apoptosis. Therefore total counts of blood cells
should be monitored in patients under treatment, to de-
tect changes. Fig. 6 illustrates the pathways blocked by
propranolol via its action as an antagonist of β2 ligands.
Although the clinical trial is now complete, we have
planned to continue the follow -up of the six patients.
Among them, 4 patients have decided to continue taking
the drug as a compassionate use of a drug under investi-
gation. These data will be useful to establish the effect
on the retina during a long-term use. Two patients de-
cided to abandon the treatment. We will also follow-up
these patients to collect data of their evolution too (be-
fore and after study).
Given that some recent publications suggest that the
optimal dosage of propranolol for a complete recession of
infantile haemangioma is around 3 mg/kg [39], this
dose should be equivalent to the highest dose used in
our in vitro experiments (100 μM) [34]. Thus, we
have consulted with our ophthalmologist and cardiolo-
gist about the possibility of initiating another clinical
trial with a higher dose of propranolol, closer to
3 mg/kg of body weight, including more patients and
with fewer previous interventionist treatments. It
would also be advisable to have a longer follow-up of
patients, of at least 3 years.
Due to the excellent response of the retinal exudation
to the treatment with propranolol, more patients with
this condition should be included, to confirm these ini-
tial results in the present clinical trial.
The results of the clinical trial, together with the previ-
ous in vitro knowledge generated in our first publication
of OJRD [34] led to the recent orphan drug designation
of propranolol by EMA to treat von Hippel Lindau dis-
ease EU/3/17/1841.
Conclusions
The fact that all the retinal tumours remained stable and
no new tumours appeared during the follow-up period,
without any other treatment but propranolol suggests
that propranolol is a promising therapeutic drug for ret-
inal haemangioblastomas, and perhaps for other ocular
pathologies with retinal exudation and high VEGF levels
(as macular degeneration). It would be convenient to ex-
plore the use of higher dosages (i.e., closer to 3 mg/kg
body weight/day).
The results of the clinical trial, together with the previ-
ous publication in OJRD [35] led to the orphan drug
designation of propranolol by EMA to treat von Hippel
Lindau disease EU/3/17/1841.
The evolution of VEGF and miRNA 210 in all the pa-
tients throughout the study, which paralleled the inactiv-
ity of the retinal disease, suggest that they may be useful
as biomarkers of VHL disease activity. To the best of
our knowledge, these are the first biomarkers described
in the literature to monitor the VHL disease activity.
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